spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS

Merck Serono

Leading science and technology company announces that it will provide its Provantage services to Acticor Biotech SAS

  • Accelerates development and manufacture of Acticor's antibody fragment that treats ischemic stroke
Darmstadt, Germany, December 5, 2016 - Merck, a leading science and technology company, today announced that it will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor's antibody fragment used for the primary treatment of ischemic stroke.

Merck's Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization.

"Our Provantage® End-to-End solution will provide Acticor with a fast and flexible approach to development and clinical-scale manufacturing," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "We look forward to executing full process development for the antibody fragment, which will help accelerate this important new molecule through the pipeline to patients in need."

The turnkey package includes process development, cGMP clinical manufacturing, quality and regulatory support, training, commercial facilities design, engineering and build-up as well as production equipment supply and process technical transfer activities.

"Stroke is the third leading cause of death in the world and the first cause of disabilities in adults," said Gilles Avenard, CEO, Acticor Biotech. "Motivated by these statistics, we are developing innovative therapeutic strategies for safe and effective emergency treatment of the acute phase of ischemic strokes. Through our collaboration with Merck, we now have access to a comprehensive set of development and manufacturing services that will help us deliver on our mission."

Merck's Provantage® End-to-End solution delivers important benefits and addresses key challenges for biopharmaceutical companies at all life cycle stages in any geography, including established biopharmaceutical companies decentralizing manufacturing that must rapidly and efficiently establish local production capabilities. With an end-to-end approach, Merck can facilitate and accelerate transfer of an entire process to a new location. Early-stage companies with limited manufacturing capabilities, resources and infrastructure benefit from a partner with best-in-class unit operations and the support and expertise to develop processes and production facilities.
phone +44 (0) 20 8818 7200
email http://www.merckserono.co.uk/en/index.html
email Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Rentschler Biotechnologie GmbH Announces Transition into a European Corporation Called Rentschler Biopharma SE


More info >>


White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement